• Molecular NameMephentermine
  • SynonymMefenterdrin; Mefentermin; Mephenterdrine; Mephenterdrinum; Mephetedrine; N-methylphentermine
  • Weight163.264
  • Drugbank_IDDB01365
  • ACS_NO100-92-5
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.65
  • pka10.4
  • LogD (pH=7, predicted)-0.23
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)0.79
  • LogSw (predicted, AB/LogsW2.0)1.16
  • Sw (mg/ml) (predicted, ACD/Labs)4.07
  • No.of HBond Donors1
  • No.of HBond Acceptors1
  • No.of Rotatable Bonds3
  • TPSA12.03
  • StatusFDA approved
  • Administrationparenterally
  • PharmacologyA cardiac stimulant. It was formerly used in Wyamine nasal decongestant inhalers and before that as a stimulant in psychiatry.
  • Absorption_valueN/A
  • Absorption (description)Readily absorbed after oral or parenteral administration
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmRapidly metabolised by demethylation and hydroxylation.
  • Half lifeDerived from urinary excretion data, about 6 to 20 h
  • ExcretionAbout 50 to 85% of a dose is excreted in the urine unchanged, together with 15 to 20% as phentermine. Conjugated N-hydroxymephentermine has also been detected in the urine in small quantities.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe estimated minimum lethal dose in children up to 2 years of age is 200 mg, and in adults is 2 g.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A